FCC Approves Expansion of SpaceX Starlink Network With 7,500 New Satellites 
OpenAI Sets $50 Billion Stock Grant Pool, Boosting Employee Equity and Valuation Outlook 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
AustralianSuper Backs BlueScope Steel’s Rejection of $9 Billion Takeover Bid 
Elon Musk Says X Will Open-Source Its Algorithm Amid EU Scrutiny 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
xAI Cash Burn Highlights the High Cost of Competing in Generative AI 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
Vitol to Ship First U.S. Naphtha Cargo to Venezuela Under New Oil Supply Deal 
Nvidia Appoints Former Google Executive Alison Wagonfeld as First Chief Marketing Officer 
Aktis Oncology Prices Upsized IPO at $18, Raising $318 Million in Major Biotech Debut 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Rio Tinto–Glencore Merger Talks Spark Investor Debate Over Value, Strategy and Coal Exposure 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
EU Orders Elon Musk’s X to Preserve Grok AI Data Amid Probe Into Illegal Content 
Johnson & Johnson Secures Tariff Exemption by Agreeing to Lower Drug Prices in the U.S. 
BOTHELL, Wash., April 08, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the prevention of migraine, Congenital Adrenal Hyperplasia, Cushing’s disease and autoimmune and inflammatory diseases, today announced that it will webcast its presentation at the upcoming 15th Annual Needham Healthcare Conference at 8:00 a.m. ET on Tuesday, April 12, 2016 in New York, NY. The presentation will feature a business overview and update by Mark J. Litton, Ph.D., Alder’s chief business officer.
A live audio webcast can be accessed on the Events & Presentations page of the Investors section of Alder’s website at http://www.alderbio.com, or by following the link below in your web browser. An archived replay of the webcast will be available on Alder’s website for 30 days after the live event concludes.
Link: http://wsw.com/webcast/needham76/aldr
About Alder BioPharmaceuticals, Inc.
Alder BioPharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. ALD403, Alder's lead pivotal-stage product candidate being evaluated for migraine prevention, is a genetically engineered monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP). CGRP is a small protein with a well-established role in the initiation, transmission and heightened sensitivity to migraine pain. Alder's second program, ALD1613, targets adrenocorticotropic hormone (ACTH) and is intended for the treatment of Congenital Adrenal Hyperplasia and Cushing's Disease. ALD1613 is undergoing Investigational New Drug (IND)-enabling preclinical studies, and an IND submission is planned for 2016. Additionally, Alder’s clazakizumab is designed to block the pro-inflammatory cytokine IL-6 and has completed two successful Phase 2b clinical trials. Alder is seeking strategic opportunities for clazakizumab. For more information, please visit http://www.alderbio.com.
Forward-Looking Statements
This press release contains forward-looking statements, including, without limitation, statements relating to: the continued development and clinical, therapeutic and commercial potential of ALD403, ALD1613 and clazakizumab; future regulatory filings; and the pursuit of strategic opportunities for clazakizumab. Words such as “potential,” “intended,” “planned,” “seeking,” or other similar expressions, identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements. The forward-looking statements in this press release are based upon Alder's current plans, assumptions, beliefs, expectations, estimates and projections, and involve substantial risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: risks related to the potential failure of ALD403, ALD1613 and clazakizumab to demonstrate safety and efficacy in clinical testing; the availability of data at the expected times; the clinical, therapeutic and commercial value of ALD403, ALD1613 and clazakizumab; risks and uncertainties related to regulatory review and approval processes and Alder's compliance with applicable legal and regulatory requirements; and other factors discussed under the caption "Risk Factors" in Alder’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, which was filed with the Securities and Exchange Commission (SEC) on February 23, 2016, and is available on the SEC's website at www.sec.gov. Additional information will also be set forth in Alder’s other reports and filings it will make with the SEC from time to time. The forward-looking statements made in this press release speak only as of the date of this press release. Alder expressly disclaims any duty, obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Alder's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
Media Contacts: David Schull or Lena Evans Russo Partners, LLC (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contact: David Walsey Alder Biopharmaceuticals (425) 408-8032 [email protected]
